INTRODUCTION: This randomized, controlled, Phase III non-inferiority clinical trial aimed to determine whether herbal therapy with Canephron® N (BNO 1045) is non-inferior to fosfomycin trometamol (FT) in treating acute lower uncomplicated urinary tract infections (uUTIs). MATERIALS AND METHODS:Women aged 18-70 years with typical symptoms of newly diagnosed acute lower uUTIs were randomized to BNO 1045 (n = 325) or FT (n = 334), with corresponding matched placebo. The primary endpoint was the proportion of patients who received additional antibiotics (ABs) to treat uUTIs between Days 1 and 38 ±3. RESULTS: Between Days 1 and 38, 238 (83.5%) patients in the BNO 1045 group and 272 (89.8%) patients in the FT group received no additional ABs. At a 15% non-inferiority margin, BNO 1045 was non-inferior to FT in treating uUTIs (non-AB rate difference: -6.26%; 95% CI -11.99 to -0.53%; 2-sided p = 0.0014). Adverse event rates were similar between groups, with higher rates of gastrointestinal disorders in the FT group and pyelonephritis in the BNO 1045 group. During the trial, no patient died or discontinued due to a treatment-related adverse event. CONCLUSIONS:BNO 1045 has the potential to reduce outpatient use of ABs for uUTIs and thus may have a significant impact on antimicrobial stewardship strategies. TRIAL REGISTRATION: NCT02639520, EudraCT number 2013-004529-99. The Author(s). Published by S. Karger AG, Basel.
RCT Entities:
INTRODUCTION: This randomized, controlled, Phase III non-inferiority clinical trial aimed to determine whether herbal therapy with Canephron® N (BNO 1045) is non-inferior to fosfomycin trometamol (FT) in treating acute lower uncomplicated urinary tract infections (uUTIs). MATERIALS AND METHODS:Women aged 18-70 years with typical symptoms of newly diagnosed acute lower uUTIs were randomized to BNO 1045 (n = 325) or FT (n = 334), with corresponding matched placebo. The primary endpoint was the proportion of patients who received additional antibiotics (ABs) to treat uUTIs between Days 1 and 38 ±3. RESULTS: Between Days 1 and 38, 238 (83.5%) patients in the BNO 1045 group and 272 (89.8%) patients in the FT group received no additional ABs. At a 15% non-inferiority margin, BNO 1045 was non-inferior to FT in treating uUTIs (non-AB rate difference: -6.26%; 95% CI -11.99 to -0.53%; 2-sided p = 0.0014). Adverse event rates were similar between groups, with higher rates of gastrointestinal disorders in the FT group and pyelonephritis in the BNO 1045 group. During the trial, no patient died or discontinued due to a treatment-related adverse event. CONCLUSIONS: BNO 1045 has the potential to reduce outpatient use of ABs for uUTIs and thus may have a significant impact on antimicrobial stewardship strategies. TRIAL REGISTRATION: NCT02639520, EudraCT number 2013-004529-99. The Author(s). Published by S. Karger AG, Basel.
Authors: T C M Christiaens; M De Meyere; G Verschraegen; W Peersman; S Heytens; J M De Maeseneer Journal: Br J Gen Pract Date: 2002-09 Impact factor: 5.386
Authors: Matthew Dixon; Maria Stefil; Michael McDonald; Truls Erik Bjerklund-Johansen; Kurt Naber; Florian Wagenlehner; Vladimir Mouraviev Journal: World J Urol Date: 2019-04-03 Impact factor: 4.226
Authors: Rachel E Hudson; Kathleen M Job; Casey L Sayre; Lubov V Krepkova; Catherine M Sherwin; Elena Y Enioutina Journal: Front Pharmacol Date: 2022-04-27 Impact factor: 5.988
Authors: Jakhongir F Alidjanov; Kurt G Naber; Adrian Pilatz; Abdukhamid Radzhabov; Musluhuddin Zamuddinov; András Magyar; Peter Tenke; Florian M Wagenlehner Journal: World J Urol Date: 2019-04-19 Impact factor: 4.226
Authors: J F Alidjanov; K G Naber; A Pilatz; A Radzhabov; M Zamuddinov; A Magyar; P Tenke; F M Wagenlehner Journal: World J Urol Date: 2019-09-23 Impact factor: 4.226
Authors: Jakhongir F Alidjanov; Andre Overesch; Dimitri Abramov-Sommariva; Martina Hoeller; Hubert Steindl; Florian M Wagenlehner; Kurt G Naber Journal: Investig Clin Urol Date: 2020-09
Authors: Jakhongir F Alidjanov; Ulugbek A Khudaybergenov; Bekhzod A Ayubov; Adrian Pilatz; Stefan Mohr; Julia C Münst; Olivia N Ziviello Yuen; Sabine Pilatz; Corina Christmann; Florian Dittmar; Nodir M Mirsaidov; Mareike Buch-Heberling; Kurt G Naber; Truls E Bjerklund Johansen; Florian M E Wagenlehner Journal: Int Urogynecol J Date: 2021-06-25 Impact factor: 2.894